Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17062167 | 0.86 | IDO1 (0.41) | IDO1RHOCRHOATACR1TSHR | |
| SCHEMBL1434343 | 0.86 | IDO1 (0.41) | IDO1DAOTAAR1RXRARXRB | |
| SCHEMBL25368340 | 0.84 | NOTUM (0.40) | IDO1DAORHOCRHOATAAR1 | |
| SCHEMBL17703913 | 0.84 | IDO1 (0.39) | IDO1CES2DAORHOCRHOA | |
| SCHEMBL3950720 | 0.80 | MRGPRX4 (0.38) | IDO1RXRARXRBRXRGTACR1 | |
| SCHEMBL265486 | 0.79 | IDO1 (0.52) | IDO1CES2DAORXRARXRB | |
| SCHEMBL27789872 | 0.78 | IDO1 (0.35) | IDO1TACR1 | |
| SCHEMBL5249761 | 0.78 | IDO1 (0.56) | IDO1CES2DAOTAAR1RXRA | |
| SCHEMBL2877529 | 0.77 | TSHR (0.50) | IDO1TSHR | |
| SCHEMBL29824490 | 0.77 | TAAR1 (0.60) | IDO1TAAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116661402-B | Production control method and system for chemical materials | 北京盛世利科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116661402-A | Production control method and system for chemical materials | 北京盛世利科技有限公司 | 2023-08-29 | — | — | CN | claimed |
| EP-1993991-B1 | PROCESS FOR THE PREPARATION OF 3,5-BIS (TRIFLUOROMETHYL)-N-METHYLBENZYLAMINE | MITENI SPA (IT) | 2010-09-22 | — | — | EP | claimed |
| EP-1993991-A2 | PROCESS FOR THE PREPARATION OF 3,5-BIS (TRIFLUOROMETHYL)-N-METHYLBENZYLAMINE | MITENI S.p.A. (IT) | 2008-11-26 | — | — | EP | claimed |
| WO-2007107818-A2 | PROCESS FOR THE PREPARATION OF 3,5-BIS (TRIFLUOROMETHYL)-N-METHYLBENZYLAMINE | MITENI S.P.A. (IT) | 2007-09-27 | — | — | WO | claimed |
| CN-119528810-B | Quinoline compound and application thereof | 山东第一医科大学(山东省医学科学院) | 2025-04-29 | — | — | CN | disclosed |
| CN-119528810-A | Quinoline compound and application thereof | 山东第一医科大学(山东省医学科学院) | 2025-02-28 | — | — | CN | disclosed |
| CN-119264124-B | Thiazolidinedione compound containing quinoline structure and application thereof | 山东第一医科大学(山东省医学科学院) | 2025-02-14 | — | — | CN | disclosed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| CN-119264124-A | Thiazolidinedione compound containing quinoline structure and application thereof | 山东第一医科大学(山东省医学科学院) | 2025-01-07 | — | — | CN | disclosed |
| CN-220370758-U | Dampproof device | 北京盛世利科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-220370825-U | Mixing stirring equipment | 北京盛世利科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995015311-A1 | TACHYKININ ANTAGONISTS | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1995-06-08 | — | — | WO | disclosed |
| WO-1994019367-A1 | SPIRO PIPERIDINES AND HOMOLOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0009787-B2 | PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION | BAYER AG (DE) | 1986-07-09 | — | — | EP | disclosed |
| US-4331821-A | ULTRAVIOLET RADIATION OF A VAPORIZED ALKYLBENZEN AND HALOGEN GAS MIXTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0009787-A2 | Process for the monohalogenation of alkylbenzenes in alpha position | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | IDO1 752/4885CES2 426/4885DAO 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.